One such lawsuit is Christie Marshman v. Bayer Pharma AG (case number 3:09-md-2100-DHRP-CJP, US District Court, Southern District of Illinois). In that case, the court filings refer to “Yaz/Yasmin/Beyaz” as a group. All three drugs are combination oral contraceptives made by Bayer.
Combination oral contraceptives are birth control pills that contain both an estrogen and a progestin component. In all three cases, the estrogen component is ethinyl estradiol and the progestin is drospirenone. Drospirenone has been linked to an increased risk of deep vein thrombosis and stroke.
Yaz contains 0.03 milligrams of ethinyl estradiol, while Yaz and Beyaz contain 0.02 milligrams. All three drugs contain 3 milligrams of drospirenone. Beyaz, however, has an additional component of 0.451 milligrams of folate (levomefolate calcium). According to court documents in the Marshman lawsuit, although there are other combination oral contraceptives on the market, Yasmin/Yaz/Beyaz are the first to use drospirenone.
The lawsuit argues that studies performed before the contraceptives were approved for use suggested drospirenone has side effects that are potentially more dangerous than those associated with older birth control pills. One possible reason for the suggested increased risk - as mentioned in the lawsuit - is an increase in blood potassium levels, which can cause hyperkalemia. Hyperkalemia can cause changes to the heart rhythm, which can slow the flow of blood, allowing blood clots to form. Blood clots are linked to heart attacks and strokes.
READ MORE BEYAZ LEGAL NEWS
Lawsuits have been filed against Bayer concerning the risk of side effects associated with Yaz/Yasmin/Beyaz. They allege women were not adequately warned about the potential for increased risks.